Thrombogenics NV (THR.BR)
28.82EUR
11:35am EDT
€-0.90 (-3.03%)
€29.72
€29.93
€29.95
€28.80
209,349
216,437
€47.82
€20.25
THR.BR
About
Overall
| Beta: | 0.46 |
| Market Cap (Mil.): | €1,072.72 |
| Shares Outstanding (Mil.): | 36.09 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| THR.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 32.23 | 34.45 | 32.18 |
| EPS (TTM): | 0.92 | -- | -- |
| ROI: | 17.58 | -2.81 | 18.91 |
| ROE: | 17.58 | -3.51 | 19.87 |
British healthcare body recommends Thrombogenics drug
BRUSSELS - Belgian biotech group Thrombogenics said on Wednesday that it received a positive initial recommendation from British healthcare body NICE that its eye drug Jetrea qualify for reimbursement to patients.
British healthcare body recommends Thrombogenics drug
BRUSSELS, June 12 - Belgian biotech group Thrombogenics said on Wednesday that it received a positive initial recommendation from British healthcare body NICE that its eye drug Jetrea qualify for reimbursement to patients.
ThromboGenics eye drug endorsed by UK cost agency
LONDON, June 12 - A new eye drug from Belgian biotechnology company ThromboGenics has been recommended for use on Britain's state healthcare service by the cost watchdog NICE.
BRIEF-ThromboGenics licenses technology from Eleven Biotherapeutics
BRUSSELS, May 28 - ThromboGenics NV : * Says licenses technology from Eleven Biotherapeutics * Says Eleven deal covers diabetic eye disease drugs
ThromboGenics says U.S. sales of Jetrea top $10 million
BRUSSELS, May 16 - Belgian drug developer ThromboGenics said on Thursday U.S. sales of its eye drug Jetrea have exceeded $10 million, after the drug was launched there at the start of the year.
ThromboGenics to get 45 mln euro payment after UK drug launch
BRUSSELS, April 12 - ThromboGenics, the Belgian biotechnology company whose main product was approved in Europe last month, said it will receive a 45 million euro ($59 million) milestone payment following the eye treatment's British launch.
BRIEF-Thrombogenics to resume trading at 1430 CET - regulator
BRUSSELS, March 15 - Thrombogenics NV : * Shares to resume trading at 1430 cet - Belgian regulator
BRIEF-Thrombogenics shares suspended - regulator
BRUSSELS, March 15 - Thrombogenics NV : * Shares suspended pending announcement - regulator
BRIEF-Thrombogenics shares to resume trading - regulator
BRUSSELS, Jan 18 - Thrombogenics NV : * Shares to resume trading at 1215 gmt - regulator
BRIEF-Thrombogenics suspended pending announcement - regulator
BRUSSELS, Jan 18 - Thrombogenics NV : * Shares suspended pending announcement - regulator
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
